Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Collegium PharmaceuticalSTU:354 78 Current Ratio is 1.71 as of Mar. 2026, which is 41% above its 10-year median of 1.21. GuruFocus rates STU:354 with a GF Score™ of 78/100 and a GF Value™ of €45.71 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 999 Drug Manufacturers companies, Collegium Pharmaceutical ranks worse than 58.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Collegium Pharmaceutical's current ratio for the quarter that ended in Mar. 2026 was 1.71.
Collegium Pharmaceutical has a current ratio of 1.71. It generally indicates good short-term financial strength.
The historical rank and industry rank for Collegium Pharmaceutical's Current Ratio or its related term are showing as below:
STU:354'
s Current Ratio Range Over the Past 10 Years
Min: 0.78 Med: 1.21 Max: 6.4
Current: 1.71
During the past 13 years, Collegium Pharmaceutical's highest Current Ratio was 6.40. The lowest was 0.78. And the median was 1.21.
STU:354's Current Ratio is ranked worse than 58.56% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs STU:354: 1.71
Collegium Pharmaceutical (STU:354) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Collegium Pharmaceutical Current Ratio Related Terms
Collegium Pharmaceutical Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:354 vs ETON, ALVO, PCRX: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's Current Ratio distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (STU:354) has a Current Ratio of 1.71 as of Mar. 2026. This is 41% above median its historical median of 1.21. Over the past decade, Collegium Pharmaceutical's Current Ratio has ranged from 0.78 to 6.40. According to the industry distribution chart, Collegium Pharmaceutical ranks #585 out of 999 companies in the Drug Manufacturers industry, placing it in the top 58.6%.
Is Collegium Pharmaceutical's Current Ratio too high?
Collegium Pharmaceutical's current Current Ratio of 1.71 is 41% above median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 6.40. The Drug Manufacturers industry median Current Ratio is 1.98. Collegium Pharmaceutical's value of 1.71 is 13.6% below this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #585 out of 999 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Collegium Pharmaceutical has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's Current Ratio compare to ETON and ALVO?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #585 out of 999 companies for Current Ratio. This places Collegium Pharmaceutical in the lower half of its industry. The industry median Current Ratio is 1.98. Collegium Pharmaceutical's value of 1.71 is 13.6% below this benchmark. Historically, Collegium Pharmaceutical's own Current Ratio has ranged from 0.78 to 6.40 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 1.98, Collegium Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.98, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current Current Ratio of 1.71 is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current Current Ratio is 1.71, which is 41% above median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (STU:354) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.71, compared to a current price of €30.80 — trading 32.6% below its estimated fair value. The current Current Ratio is 1.71, which is 41% above median its 10-year median of 1.21 and 13.6% below the Drug Manufacturers industry median of 1.98. Collegium Pharmaceutical's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Collegium Pharmaceutical (STU:354), the current Current Ratio is 1.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (STU:354) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of €30.80 is trading 32.6% below its estimated GF Value™ of €45.71.
GuruFocus considers Collegium Pharmaceutical to be Modestly Undervalued.
Key valuation signals for STU:354:
Current Ratio: 1.71 (41% above median its 10-year median of 1.21)
GF Value™: €45.71 vs. price of €30.80 (32.6% below fair value)
Industry Position: 13.6% below the Drug Manufacturers median (#585 of 999)
No single metric tells the full story. See the STU:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
78GF Score
Get the complete analysis for STU:354
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:354 has been successfully added to your 
